

Table I. *The distribution of total 240 samples within the 24 patient groups.*

Patient/Tumor characteristics	AA samples	CA samples
Control, pre-menopausal	10	10
Control, post-menopausal	10	10
TN, pre-	15	10
TN, post-	14	10
HER2+, pre-	6	10
HER2+, post-	1	10
LA, pre-	10	10
LA, post-	8	10
LB1, pre-	15	10
LB1, post-	22	10
LB2, pre-	5	10
LB2, post-	4	10

AA: African American; CA: Caucasian American; TN: triple-negative subtype (ER-/PR-/HER-); Her2+: human epidermal growth factor receptor 2 subtype (ER-/PR-/HER2+); LA: Luminal A subtype (ER+, Ki67-); LB1: Luminal B1 subtype (ER+, HER2+); LB2: Luminal B2 subtype (ER+, HER2+).